Leerink Partnrs Has Negative Outlook for BBIO Q3 Earnings

BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) - Equities researchers at Leerink Partnrs lowered their Q3 2025 earnings per share estimates for shares of BridgeBio Pharma in a research report issued on Monday, June 30th. Leerink Partnrs analyst M. Foroohar now anticipates that the company will post earnings per share of ($0.79) for the quarter, down from their prior estimate of ($0.78). The consensus estimate for BridgeBio Pharma's current full-year earnings is ($3.67) per share. Leerink Partnrs also issued estimates for BridgeBio Pharma's Q4 2025 earnings at ($0.60) EPS, FY2025 earnings at ($2.87) EPS, FY2026 earnings at ($1.46) EPS, FY2027 earnings at $0.66 EPS, FY2028 earnings at $3.50 EPS and FY2029 earnings at $5.52 EPS.

BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last issued its earnings results on Tuesday, April 29th. The company reported ($0.88) EPS for the quarter, beating analysts' consensus estimates of ($1.00) by $0.12. The firm had revenue of $36.74 million during the quarter, compared to analyst estimates of $57.14 million. The business's revenue for the quarter was down 44.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.20) earnings per share.

A number of other analysts have also recently weighed in on the stock. Piper Sandler upped their target price on shares of BridgeBio Pharma from $46.00 to $63.00 and gave the company an "overweight" rating in a research note on Wednesday, April 30th. Redburn Atlantic started coverage on BridgeBio Pharma in a report on Monday, March 31st. They set a "buy" rating and a $50.00 price objective on the stock. Scotiabank upped their price objective on BridgeBio Pharma from $52.00 to $55.00 and gave the company a "sector outperform" rating in a research note on Wednesday, April 30th. Bank of America increased their target price on BridgeBio Pharma from $50.00 to $54.00 and gave the stock a "buy" rating in a report on Wednesday, June 25th. Finally, UBS Group boosted their price target on BridgeBio Pharma from $65.00 to $72.00 and gave the company a "buy" rating in a research note on Wednesday, April 30th. Two analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to data from MarketBeat, BridgeBio Pharma currently has an average rating of "Moderate Buy" and an average price target of $58.85.

BridgeBio Pharma Stock Up 2.0%

BridgeBio Pharma stock traded up $0.88 on Thursday, hitting $43.71. The company's stock had a trading volume of 2,459,721 shares, compared to its average volume of 2,510,237. BridgeBio Pharma has a one year low of $21.72 and a one year high of $45.48. The firm has a market cap of $8.30 billion, a P/E ratio of -12.38 and a beta of 1.15. The company has a fifty day moving average price of $37.93 and a 200-day moving average price of $34.75.

Insider Buying and Selling

In related news, major shareholder Global Investors Lp Viking sold 3,500,000 shares of the company's stock in a transaction dated Friday, June 27th. The shares were sold at an average price of $44.00, for a total transaction of $154,000,000.00. Following the transaction, the insider owned 18,555,375 shares in the company, valued at $816,436,500. This represents a 15.87% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Neil Kumar sold 75,000 shares of the stock in a transaction dated Tuesday, April 22nd. The stock was sold at an average price of $34.11, for a total transaction of $2,558,250.00. Following the sale, the chief executive officer directly owned 4,873,447 shares in the company, valued at approximately $166,233,277.17. This represents a 1.52% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 9,936,181 shares of company stock valued at $375,878,164. Insiders own 18.20% of the company's stock.

Institutional Trading of BridgeBio Pharma

A number of hedge funds and other institutional investors have recently modified their holdings of BBIO. Rhumbline Advisers lifted its holdings in BridgeBio Pharma by 0.5% during the 1st quarter. Rhumbline Advisers now owns 220,128 shares of the company's stock worth $7,610,000 after buying an additional 1,008 shares in the last quarter. Strs Ohio bought a new stake in shares of BridgeBio Pharma during the first quarter worth $408,000. Wealth Management Associates Inc. raised its position in shares of BridgeBio Pharma by 19.0% during the first quarter. Wealth Management Associates Inc. now owns 8,980 shares of the company's stock worth $310,000 after acquiring an additional 1,435 shares during the last quarter. Intech Investment Management LLC lifted its stake in shares of BridgeBio Pharma by 12.0% during the first quarter. Intech Investment Management LLC now owns 73,524 shares of the company's stock valued at $2,542,000 after acquiring an additional 7,877 shares during the period. Finally, Zimmer Partners LP boosted its holdings in BridgeBio Pharma by 67.1% in the first quarter. Zimmer Partners LP now owns 301,400 shares of the company's stock valued at $10,419,000 after acquiring an additional 121,000 shares during the last quarter. Institutional investors and hedge funds own 99.85% of the company's stock.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.